# Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

> **NCT03125200** · PHASE1 · TERMINATED · sponsor: **ADC Therapeutics S.A.** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer
- Non Small Cell Lung Cancer
- GastroEsophageal Cancer
- Bladder Cancer

## Interventions

- **DRUG:** ADCT-502

## Key facts

- **NCT ID:** NCT03125200
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-18
- **Primary completion:** 2018-04-05
- **Final completion:** 2018-04-05
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Safety
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125200, "Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03125200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*